CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 28 enrolled
Drug / intervention
Lithium Carbonatedrug
Likely dose
Lithium Carbonate 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00870311
NCT00870311Phase 4Completed
CompareCT.gov

Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients

Wayne State University·interventional·Posted Mar 27, 2009·Updated Mar 27, 2009

In Brief

A Phase 4 clinical trial evaluating Lithium Carbonate for Bipolar Disorder. Completed, enrolled 28 participants across 1 site.

Detailed Summary

This study investigates the effects of Lithium treatment on signal transduction pathways, gene expression and brain neurochemistry and structure in patients with Bipolar disorder. It is hypothesized that specific changes in these markers will correlate with lithium treatment responsiveness.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBipolar Disorder
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 27, 2009
Enrollment StartMar 1, 1996
Primary CompletionApr 1, 2004
TodayJul 2, 2026
Enrollment to primary: 8.1 yearsPosted 17.3 years ago

Interventions

Lithium Carbonatedrug

300mg PO, three times daily with dose titrated to obtain a therapeutic plasma level of 0.8 to 1.2meq/L) over the first week of treatment. Total duration is a minimum of 3 weeks. Medication is dispensed in the form of blinded research capsules.